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Abstract
Infections are responsible for over half a million neonatal deaths every year
(Lawn et al., 2014). Thus, there is huge interest in leveraging maternal immunization
against infectious diseases to grant fetal protection during its development through the
vertical transferring of IgG antibodies, the only Ig subclass that can significantly cross
the placental barrier.
Studies about vertical immunization rely on in-vitro models to extrapolate
physiological conditions of the human placenta. The BeWo Transwell model (Bode et
al., 2006) presents itself as a reliable model to mimic the transplacental transport
mechanism of antibodies (Ellinger et al., 1999; Poulsen et al., 2009). However, despite
being a consolidated method, the BeWo Transwell preparation has a wide variation of
parameters. Additionally, up to this date, evaluation of preferential transfer of IgG
considering its subclasses and specificities have not been reported in the BeWo
Transwell, limiting the ability to assess the reliability of this model for antibody
translocation studies.
Therefore, the focus of this project is to investigate the effect of IgG subclasses
and specificity in the placental transferring of 16 CMV antibodies designed in-house
by using the BeWo Transwell model in order to contribute to in-vitro studies about
maternal immunization. However, the success of this study relies on first optimizing
the Transwell model towards a more time-efficient preparation to reach monolayer
confluency by investigating three variables: membrane coating, cell seeding density,
and incubation time.
Results indicate that the final ideal parameters for the Transwell setup are
collagen-coat over the microporous membrane, seeding cell density of 6 × 10!
cells/#$" (200,000 cells/well for the 24-well plate), and incubation time of 72 hrs (3
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days). Comparison of the preferential transfer of IgG across this BeWo Transwell
model revealed that IgG4 1G2 has the best transferring performance. In the context of
IgG subclasses, IgG3 has the worst relative transferring, regardless of its specificity.
On the other hand, IgG4 and IgG2 show the best relative transferring performance
overall. Analysis of the data by mAb specificities reveals that IgG 1G2 has the best
transferring performance across the cell layer, regardless of its subclass.
Future directions include quantifying the IgG transferring across the cell layer
for a statistical analysis, and investigations about how mAb specificity influences IgG
subclass transport across the BeWo cell layer, and how the transferring is compared to
those found in-vivo.
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Introduction
Monoclonal antibodies in immunotherapy

Antibodies, also called immunoglobulins (Ig), are glycoprotein molecules
produced by plasma cells that play a critical role in identifying and binding to foreign
objects such as bacteria and viruses, assisting the immune system in fighting against
diseases (Branden & Tooze, 1999). Monoclonal antibodies (mAbs) work in a similar
fashion but are engineered in the laboratory and intentionally tailored to target an
antigen. The ability to design specific modifications in mAbs, make them a powerful
tool to effectively and safely target diseases that, up to recent years, did not have a cure,
and to leverage immunotherapy in several contexts, from cancer therapy to vaccine
development (Brekke & Sandlie, 2003). Currently, monoclonal antibody research is
one of the fastest-growing fields in biotechnology due to its pharmaceutical
applications. For instance, the top selling drug globally in 2019 was a mAb (Urquhart,
2020).

Immune system and the role of antibodies

Our immune system can be segmented into innate and adaptive. The first line
of defense against general pathogens, the innate immune system does not change based
on its exposure to diseases. The adaptive immune system, on the other hand, is activated
by signals delivered from the innate system and uses an immunological memory to store
information about previous threats. By making use of lymphocytes and antibodies, the
adaptive immune system uses antigens to trigger an immune response against specific
diseases. In antibody responses, antibodies circulate in the bloodstream and bind to
foreign substances, blocking the pathogen from binding to receptors on host cells and
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marking them for destruction. Given their specificity and efficacy, antibodies are key
components of our immune defense (Hoebe et al., 2004).
There are five antibody types circulating in the human body: IgA, IgD, IgE,
IgG, and IgM. Out of these antibody isotopes, the IgG is the most common antibody in
the plasma, accounting for 70% of immunoglobulins in the human body (Llewelyn et
al., 1992). IgG is also the only antibody isotope transferred in significant quantities
from the mom to the fetus through the placental tissue during pregnancy, making it
particularly important for studies on maternal vaccination, passive immunization, and
neonatal infection (Malek et al., 1996).

Structure and characterization of IgG

IgG antibodies have a Y-shape, where the stem of the Y characterizes the Fc
fragment – part that interacts with receptors of the immune response. The two arms on
the Y-shape are called Fab fragments, where two antigen-binding sites allow the
recognition of target sequences and formation of immune complexes. IgG antibodies
have a molecular weight of approximately 150 kDa and are composed of two different
peptide chains: the light chain and the heavy chain. The light chain is approximately 25
kDa and is only present on the
Fab fragments. The heavy chain
is approximately 50 kDa and is
present both in the Fc and Fab
regions. Each IgG molecule is
composed of two heavy chains,
linked

with

each

other

by

disulfide bonds, and two light

Figure 1: Stuctural schematic of IgG
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chains, linked with one heavy chain each through a disulfide bond as well. In all IgG,
the two heavy chains and the two light chains are equivalent, giving the antibody two
identical antigen-binding sites (Branden & Tooze, 1999). IgG monoclonal antibodies
conserve this same general structure, which is represented in Figure 1.
There are four subclasses of IgG, named in the order of decreasing abundance
in the blood: IgG1, IgG2, IgG3, and IgG4 (Schur, 1988). Although the tertiary structure
of IgGs is relatively similar, the location and number of interchain-disulfide bonds
differs for each subclass. The aminoacid sequence of IgG subtypes are approximately
90% homologous in the heavy chain, with differences found in the CH domains
(Jefferis et al., 1985; Vidarsson et al., 2014). These modifications give each subclass
different characteristics in immune complex formation, half-life, and placental
transport, for example (Vidarsson et al., 2014).

Figure 2: Structure of IgG subclasses. IgG: immunoglobulin G; FR: framework region; VL: variable
region of light chain; VH: variable region of heavy chain; CL constant region of light chain; CH1:
constant region of heavy chain 1; S-S: disulfide bond; H: hinge region; CH2: constant region of heavy
chain 2; CH3: constant region of heavy chain 3; CDR: complementarity-determining region; V: variable
region; D: diversity segment; J: joining segment; CHS: coding region at the C-terminal end of a secreted
immunoglobulin heavy chain; H1: hinge region 1; H2: hinge region 2; H3: hinge region 3; H4: hinge
region 4. (Structure of the IgG Subclasses - UpToDate, n.d.)
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FcRn receptor as a mediator for neonatal immunization through vertical IgG transferring

Newborn infants present an immature immune system and are particularly
susceptible to vaccine-preventable diseases. However, natural neonatal immunity can
be enhanced still at a gestational stage through maternal immunization and the resulting
vertical (mother-to-child) transfer of pathogen-specific antibodies across the placenta
(Healy, 2012; Kristoffersen, 2000; Marchant et al., 2017; Meng et al., 2018; Patel et al.,
2019). In humans, the placenta acts as a cellular barrier separating the maternal and
fetal blood. Several molecular substances are actively and passively transferred through
the placenta to the fetus, from small molecular weight substances such as ions and
aminoacids to high molecular weight proteins such as IgG antibodies (Knipp et al.,
1999; Little & VanBeveren, 1996; Malek et al., 1998; Pitcher-Wilmott et al., 1980).
In

humans,

the

mother-to-child

IgG

transfer

occurs

across

the

syncytiotrophoblast of the placenta (N. E. Simister et al., 1996; Neil E. Simister, 1998).
Syncytiotrophoblasts are in the maternal blood and involve the fetal blood, serving as
a histological barrier. The Fc neonatal receptor (FcRn) is expressed in the internal
vesicles of the syncytiotrophoblast and is responsible for mediating the transplacental
translocation of maternal IgG (F. W. R. Brambell et al., 1964; F. W. Rogers Brambell,
1966; Israel et al., 1996; Roopenian et al., 2003). The human FcRn has only one
potential glycosylation site (N102) and does not bind its IgG ligands at physiological
pH (7.4). However, when the endosome is acidified (pH ≤ 6.5), the histidine residues in
IgG are protonated and the FcRn binds to the maternal IgG, facilitating its transport into
the fetal circulation (Chaudhury et al., 2003; Gastinel et al., 1992; Roopenian et al.,
2003). Once in the baby’s bloodstream, these IgGs can protect the fetus from infections
in the developmental stage and the child during early life, since the antibodies stay in
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circulation for 6-12 months after birth (Kılıç et al., 2003; Leuridan et al., 2011; Leuridan
& Van Damme, 2007).

Figure 3: Human placenta and IgG transport mediated by the FcRn receptor. (a) Fetus in developing
stages attached to an umbilical cord and uterine wall. (b) Cross-sectional view of the placenta. (c)
Detailed diagram of the materno-fetal IgG transfer in humans across the syncytiotrophoblast of the
placenta, mediated by the FcRn receptor. Image adapted from (Pemathilaka et al., 2019).

Infections are responsible for over half a million neonatal deaths every year
(Lawn et al., 2014). Thus, there is huge interest in leveraging maternal immunization
against infectious diseases to grant fetal protection during its development and boost
the inexperienced immune system of neonates through the vertical transferring of IgG.
Previous studies have demonstrated that each IgG subclass presents a different
transport capacity across the placental tissue, with preferential transfer following the
sequence: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et al., 1994, 1996).
However, antibody specificities might influence the placental transport of different IgG
subclasses since there is variation in the subclass response to different antigens and each
subclass has a different affinity to the IgG-transporting FcRn receptors (Ferrante et al.,
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1990; Wesumperuma et al., 1999). Therefore, it is crucial for studies in maternal
immunotherapy to characterize IgG transfering in the context of IgG subclasses and
specificities.

BeWo Transwell assay as a model for placental translocation studies

Due to ethical reasons, in-vivo IgG transferring studies from mother-to-child
during fetal development remain extremely limited (Constantinos et al., 2011). Some
animals, like rodents, can assist with information on placental transfer of substances
and their potential effects to the fetus. However, the placenta is a species-specific organ
and any extrapolation from animal models to humans could lead to inaccuracies
(Schmidt et al., 2015). In order to avoid ethical issues and overcome species-specific
differences, several ex-vivo and in-vitro models using human cells or tissue have been
recently proposed (Aengenheister et al., 2018; Ellinger et al., 1999; Levkovitz et al.,
2013; Mathiesen et al., 2014).
The ex-vivo placental perfusion model uses a human term placenta obtained
directly after birth to establish a dynamic circulation mimicking the in-vivo system
(Grafmüller et al., 2013; Mathiesen et al., 2014). Despite bypassing the extrapolation
from animal data, this model has a perfusion duration of only 6 hours, has a low
throughput, is hard to reproduce due to interindividual differences, and has a success
rate dependent on the availability of fresh placentas, informed consent, and timeconsuming procedures affected by a high leakage or failure rate (Hutson et al., 2011;
Poulsen et al., 2009).
On the other hand, in-vitro translocation models are more widely used due to
their easier set-up and convenience for lab personnel. Such models use a confluent
monolayer of cells cultivated over a porous membrane to study the transport of
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substances. Despite not fully simulating the physiological structure and factors
influencing the placental barrier, this model is able to accurately represent perfusion
preferences of substances that agree with ex-vivo results and mimic transplacental
transport mechanisms (Ellinger et al., 1999; Poulsen et al., 2009).
The setup of in-vitro translocation models is depicted in Figure 4. It consists of
an upper chamber delimited by a Transwell insert, embedded into a lower chamber. The
Transwell insert has a “cup-like” shape
and its bottom is composed of a
microporous

membrane

to

allow

perfusion of the studied substance. To
model histological transfer barriers, a
cell layer is cultivated on top of a matrix
Figure 4: Schematic of the Transwell in-vitro

layered on the microporous membrane. translocation model
While much of the research

community has focused on utilizing the BeWo Transwell model to study the transport
of small substances and nano-particples, this experimental setup can have profound
implications in transport studies of IgG (Aengenheister et al., 2018; Huang et al., 2016).
In the past, there have been successful studies on the reduced transcytosis of IgG2 and
the half-life of IgG3, for example, which were conducted using the BeWo Transwell
model (Stapleton et al., 2011, 2019). However, up to this date, no study has attempted
to characterize the preferential IgG transferring in the BeWo Transwell model in the
context of subclasses and specificities. Without knowing how the IgG transfer in this
model compares to those in-vivo, extrapolation to human physiology of maternal
immunization studies using the BeWo Transwell remains limited.
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The reliability of placental transport studies using this setup rely on the
confluency of the cell monolayer and its resemblance to human physiology. In the past,
several studies attempted to optimize this model (Aengenheister et al., 2018; Bode et
al., 2006; Huang et al., 2016).
In order to simulate the in-vivo placental translocation of IgG, researchers
attempted to culture isolated syncytiotrophoblasts, but reported that such cell culture is
hard to obtain (Bode et al., 2006; Ellinger et al., 1999). Fortunately, BeWo cells derived
from human choriocarcinoma retain several characteristics of trophoblasts, the
undifferentiated cell layer of syncytiotrophoblasts, such as placental hormone secretion
and permeability. More importantly, BeWo cells express an IgG receptor structurally
and functionally homologous to the human FcRn, making them a good cell line to
extrapolate the physiology of syncytiotrophoblasts (Ellinger et al., 1999). Thus, BeWo
cells have been used as the “gold standard” in in-vitro models to investigate the
placental transport of several nutrients, proteins, and compounds, such as IgG (Ellinger
et al., 1999; Huang et al., 2016; Moe et al., 1994; Schmid et al., 2003).
However, there is still doubt about the need of the matrix layer between the
microporous membrane and the cell layer. Some research groups and unpublished
studies conducted in the Ackerman Lab indicate that coating the Transwells with
placental collagen is essential for the monolayer formation (Bode et al., 2006; Huang
et al., 2016). Contrastingly, others reported achieving monolayer integrity without a
matrix layer and observed no transport difference between collagen-coated and
uncoated membranes (Aengenheister et al., 2018; Stapleton et al., 2011, 2019).
Questions also remain about the number of seeded cells and their incubation
time to reach a confluent cell monolayer. While previous studies reported achieving
monolayer integrity with overnight cell incubation (Stapleton et al., 2011, 2019), other
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authors and unpublished studies conducted in the Ackerman Lab indicate the need of a
3-7 days incubation period for such results (Aengenheister et al., 2018; Bode et al.,
2006; Cartwright et al., 2012; Huang et al., 2016; Rytting et al., 2012). Additionally,
there is a wide variation in the seeding density of cells. In previous studies, monolayer
confluency was achieved with cell seeding density ranging from 1.0 × 10!
cells/#$" (Aengenheister et al., 2018; Cartwright et al., 2012; Liu et al., 1997) to 1×10#
cells/#$" (Huang et al., 2016).
Therefore, much remains in terms of optimizing the BeWo Transwell model for
translocation studies as well as exploring IgG transferring in this model as a means to
characterize the effect of IgG subclasses and specificity in antibody transferring across
the placental tissue in-vitro.

Antibody Selection & Justification

Cytomegalovirus (CMV) is a herpes virus that causes infection with serious
developmental impacts for newborns, who are particularly susceptible to developing
hearing loss, blindness, and cognitive delay in cases of congenital infection (Dollard et
al., 2007; Pass et al., 2006). In the United States, CMV is estimated to be the leading
cause of hearing loss in newborns, accounting for 15-21% of cases of hearing loss at
birth (Morton & Nance, 2006).
Studies about herpes simplex virus infections have shown that behavioral
sequelae in the fetus can be prevented by maternal immunization (Patel et al., 2019).
Such findings lay the groundwork for investigations on maternal vaccination as a
preventive method against neurotropic neonatal infections caused by other herpes
viruses, such as CMV.
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Previous research conducted at the Ackerman Laboratory reported the CMVspecificity of 16 different anti-CMV antibodies, which were genetically designed and
engineered in the lab by modifying IgG1, IgG2, IgG3, and IgG4 mAbs with four DNA
fragments: 1G2, 8I21, 9I6, and ITC33. As the unpublished data on Figure 5 shows,
inserting these DNA sequences into the backbone of IgG equipped the antibodies with
the feature of recognizing glycoprotein B and the glycoprotein pentamer. Such antigens
are found on the surface of the CMV virus (Chandramouli et al., 2015, 2017; Silvestri
et al., 1993), and antibodies that are able to recognize these DNA fragments are strong
candidates for use in the development of the first CMV vaccine.

Figure 5: CMV-specificity of antibodies designed in-house. IgG2 data is not depicted as the mAbs were
produced and analyzed in a subsequent study conducted by Andrew Hederman. (a) and (b) 1G2 and
ITC33 mAbs bind CMV gB. (c) and (d) 8I21 and 9I6 mAbs bind CMV pentamer. Figure from unpublished
data, Ackerman Lab. Data was collected by Sayuri Magnabosco and Jennifer Lai, and graphics were
made by Andrew Hederman.

Given the nature of the mother-to-child transmission of the congenital CMV
infection, viability of a CMV vaccine using such antibodies rely primarily on the
effectiveness of antibody transferring across the placental tissue between the fetus and
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expecting mother. However, without understanding how the IgG transport is affected
by subclasses and specificities in a reliable in-vitro model, attempts to move to in-vivo
testing and create a vaccine for CMV are limited.
Considering the need in modeling IgG transferring across the placenta in-vitro,
the vertical transmission of congenital CMV, and research efforts in our group around
a CMV vaccine, we propose this study using the 16 CMV-specific IgG mAbs
previously designed in the Ackerman Lab (Table 1).
Table 1: Antibodies selected for this study

Subclass

Specificity

Ag specificity

1G2

gB

ITC33

gB

8I21

pentamer

9I6

pentamer

IgG1
IgG2
IgG3
IgG4
IgG1
IgG2
IgG3
IgG4
IgG1
IgG2
IgG3
IgG4
IgG1

IgG2
IgG3
IgG4

The FcRn-mediated transport of antibodies relies on the binding of IgG to FcRn
through the Fc region of antibodies, a structural part that is generally conserved within
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each IgG subclass, regardless of their specificities (Burmeister et al., 1994). Therefore,
despite the CMV-specificity of the selected mAbs, results from this study will be able
to contribute to discussions about general IgG preferential transfer across the placental
tissue in in-vitro models.

Objectives and Hypotheses
The focus of this study is to investigate the effect of IgG subclasses and
specificity in the placental transferring of antibodies by using the BeWo Transwell
model in order to contribute to in-vitro studies about maternal immunization. However,
the success of this project relies on first optimizing the Transwell model to study the
transferring of IgG antibodies. Currently, the experimental preparation to achieve a
confluent cell monolayer presents wide variation in the number of seeded cells and their
incubation time, and divergent results on whether the collagen-coating of the
microporous membrane is necessary to achieve monolayer confluency. Therefore, this
research project aims to achieve the following goals:
1. Optimize the BeWo Transwell assay via investigation of seeding cell density,
incubation time, and presence/absence of a collagen matrix layer in order to
obtain a confluent cell monolayer to be used in transport studies in-vitro.
a. Hypothesis I: Transwells seeded with higher cell densities will require
less incubation time to reach monolayer confluency. Fluorescence
measurements in the lower chamber will correlate negatively with
monolayer confluency, and there will be a point where no fluorescence
in the lower chamber will be detected due to full retention of FITCdextran in the upper chamber of confluent monolayers.
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2. Compare the preferential transfer of IgG across the placental tissue in-vitro
using the BeWo Transwell model by analysis of 16 anti-CMV mAbs with
different specificities and subclasses.
a. Hypothesis II: All the samples will be able to cross the monolayer tissue,
but at different amounts. Luminex analysis will indicate higher IgG
concentrations in the lower chamber for antibody species that have the
most efficient transferring across the cell layer. Extrapolation from
human physiology indicates preferential transferring following the
sequence: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et al.,
1994, 1996). Antibodies that present the same antigen specificity should
demonstrate comparable IgG transferring capabilities.

Materials and Methods
General Experimental Design
The experiments were designed in two phases. The first part involved testing
the monolayer confluency on the Transwell inserts according to three variables: number
of seeded cells, presence/absence of collagen as a matrix between the microporous
membrane and the cell layer, and incubation time. Cell permeability based on
fluorescence reading of FITC-dextran (40kDa) was then compared to determine
optimized parameters for reaching monolayer confluency on the Transwell insert in the
most time-efficient manner. In the BeWo monolayer, only IgG antibodies should be
able to significantly cross the membrane once it has reached confluency. Thus, FITCdextran transport across the cell layer was used as an indicative of monolayer
confluency. Experiments were performed in an iterative fashion, where the fluorescent
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readouts guided further investigations on incubation time and/or cell seeding density.
Detailed experimental conditions and protocols are explained in the sections below.
The second part of the experiment involved using the optimized Transwell
model to evaluate the transferring of 16 CMV-specific mAbs (IgG1, IgG2, IgG3, and
IgG4 with 1G2, 8I21, 9I6, and ITC33 specificities). Samples were collected over time
in order to characterize the preferential transferring of antibodies based on their
subclasses and specificities. The overview of the experimental design is presented on
Figure 6.

Figure 6: Depiction of experimental design overview

Throughout this project, we used 24-well Transwell plates with polyester inserts
of pore size 0.4 μm, and 0.33 #$" growth area (Corning Costar), depicted in Figure 7.
Despite having 24 inserts, this plate is designed by the manufacturer to accommodate
only 12 Transwell inserts per plate, on the central rows B and C.
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a)

b)

Figure 7: Schematics of a 24-well Transwell plate. (a) Picture of the Transells purchased for this project
(Corning e-catalog). (b) Top view of the plate indicates the location of the 12 Transwell inserts, on rows
B and C, highlighted in pink. Amplification of a well with the Transwell insert indicates the well setup
and specifications provided by the manufacturer.

Production of Antibodies
Plasmids of the 16 CMV antibodies of interest in this study (Table 1) were
generated in a previous project in our lab by Jennifer Lai, Sayuri Magnabosco, and
Andrew Hederman. First, pMAZ vectors went under vector restriction. Enzymes NheIHF and BSSHII (NEB) were used for the pMAZ IgG1, IgG2, IgG3, and IgG4 and
enzymes BSiWI-HF and BSSII (NEB) were used for pMAZ IgL. Next, the restricted
products went under Gibson assembly reaction in VH/VL blocks to receive the DNA
fragments encoding 1G2, 8I21, 9I6, and ITC33 specificities. The product was then
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transformed into 5-alpha competent E.Coli (NEB). Colonies were picked and
inoculated for a miniprep. To verify correct gene insertion, the miniprepped DNA was
sent to Genewiz for sequencing and analyzed in Benchling. Plasmids with the correct
insert were re-transformed, grown into LB cultures with Ampicillin, and their DNA
was harvested using NucleoSpin Plasmid (no lid) purification kit (Machery-Nagel) and
following the NucleoSpin Plasmid QuickPure protocol - isolation of high-copy plasmid
DNA from E.coli (Machery-Nagel).
To produce the antibodies used in this study, the DNA products previously
produced were re-transformed into 5-alpha competent E.Coli (NEB) according to the
following protocol adapted from NEB (C2987H/C2987I):
* Perform steps 1-6 in the tube provided
1. Thaw E.Coli (stored at -80°C) for 15 min on ice before adding 1μl of the
antibody plasmid of interest
a. Make a separate tube for each CMV antibody used in this study (Table
1)
2. Incubate cells on ice for 30 min
3. Heat-shock the cells in a 42°C water bath for 30 seconds
4. Add 1ml of stable outgrowth medium (NEB) to each tube
5. Incubate tubes at 37°C for 1 hour in the rotation tray
6. Use the bunsen burner flames to create a "sterile field":
a. Plate 200μl of cells onto Luria broth (LB) agar plates with Ampicillin
7. Leave plates to grow overnight at 37°C
A single colony was picked and inoculated in 250mL of LB culture with 250μl
of 1000x Ampicillin. The cells were allowed to grow overnight at 37°C on a shaking
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platform. DNA was then harvested from the cells using PureYield Plasmid Maxiprep
System (Promega, ref. A2393).
To express the antibodies, Expi293F cells were grown to a density of
10# #%&&'/$) and transfected with expression plasmids following the Expi293F
transfection protocol (Thermo Fisher Scientific) below:
1. Day 0
a. Add 7.5 × 107 cells to 25.5 mL of Expi293 Expression Medium in a 125mL flask.
b. For each transfection, prepare the following:
i.

Dilute 30 μg of plasmid DNA in Opti-MEM Medium to a total
volume of 1.5 mL. Mix gently. Filter the DNA. For this
transfection 15 ug of light chain and 15ug of construct.

ii.

Dilute 81 μL of ExpiFectamine 293 Reagent in Opti-MEM
medium to a total volume of 1.5 mL. Mix gently and incubate
for 5 minutes at room temperature

iii.

After the 5-minute incubation, add the diluted DNA to the
diluted ExpiFectamine 293 Reagent to obtain a total volume of
3 mL. Mix gently.

iv.

Incubate the mixture for 20 minutes at room temperature to allow
the DNA-ExpiFectamine 293 Reagent complexes to form.

v.

Add 3 mL of complex to each flask. Each flask should contain
28.5 mL.

2. Day 1
a. After incubating cells for 20 hours, add 150 μL of Transfection Enhancer
1 and 1.5 mL of Transfection Enhancer 2 to each flask. (Enhancers 1
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and 2 can be combined prior to addition to the cell culture.) The final
volume should be approximately 30 mL in each 125-mL flask.
On Day 7 of the transfection, cells were harvested and spinned down. The
supernatant was filtered and purified through gravity column purification. The protocol
used is detailed below:
1. Mix resin pro A or pro G to resuspend
2. Add 1-3mL into the column and let the fluid drip out. Add until the total volume
of resin is 1-2mL (for 30 mL transfection)
3. Flow 20% ethanol (25mL). Put fret about 1 cm above top of resin
4. Flush with 25 mL 1X PBS, 0.1M NaOH, 1X PBS
5. Flow supernatant through the column. Add 10mL 1X PBS. Collect all flow
through in 50 mL conicals
6. Swap out basin with 15 mL conical holder. Add 8-10 mL 100mM glycine (pH
3) and collect
7. In the 15 mL conical put 500 uL 1M Tris HCl pH 8.
8. Add 2-4 mL 100mM glycine pH 2.7 and collect in the same 15mL conical tube.
9. Buffer exchange 3X into 1X PBS in 30k MWCO column
10. Reconstitute resin
The transfection and purification procedures for the mAbs used in this study
were performed by Andrew Hederman approximately 12 months prior to the start of
this project and were kept at 4°C.
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Cell culture and passaging

Cell culture was carried out following previously described protocols (Bode et
al., 2006). All the processes were carried out inside a class 2 biological safety hood
(SterilGARDIII Advance, The Baker Company). The BeWo human choriocarcinoma
cells used in this study originally came from ATCC, CCL-98. Cryopreserved cells at
passage 7 were obtained from the -196℃ liquid nitrogen cell storage at the Thayer
School of Engineering.
Cells were cultured in DMEM-F12 + GlutaMAX (Gibco, ref 10565-018)
containing 10% FBS (Biowest). To prepare the media, FBS stored at -20°C was thawed
in a bead bath to 37°C and mixed with the DMEM-F12 + GlutaMAX medium; the
solution was then vacuum filtered in a 0.2µm PES filter unit (VWR North American,
cat 10040-436) and stored at 4°C up to use.
Cell culture was carried out in polystyrene flasks T25 or T75 (CytoOne) with
vented filter caps having a 0.2 µm hydrophobic membrane, and maintained at 37 °C,
5% CO2, and 95% relative humidity inside an incubator (NAPCO Series 8000 WJ C02
incubator, Thermo Scientific).
First, the BeWo cell vial was thawed. Cells were slowly diluted in 20mL of prewarmed cell media, plated into a T75 cell culture flask, and let grow to confluency for
5-6 days in the incubator.
Cells were passaged when monolayer reached 80-90% confluency, which was
monitored by visual inspection with light microscopy. Cell passaging followed these
steps for a T75 cell culture flask:
1. Warm up DMEM-F12 + 10%FBS media and 0.25% Trypsin (corning), both
stored at 4°C, in a bead bath to 37°C
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2. Remove current media from cell culture flask and wash monolayer with 5mL of
new, warm media to remove dead cells; remove wash media from flask
3. Add 1mL of Trypsin, close flask and incubate for 3-5min in the incubator
4. Visualize cells under light microscope to confirm trypsinization of cells
5. Hand-tap the sides of the flask until cells detach from the flask; check for cell
suspension under the light microscope
6. Add 5mL of media to the flask to bring the total volume to 6mL, washing the
walls in order to maximize cell harvesting; vigorously pipet the solution 3 times
in order to break down cell clumps
7. Transfer the desired volume into a new cell culture vial based on the desired
split; complement flask with cell media up to volument recommended by the
vial manufacturer
a. For a 1:2 split from a T75 flask to a T75 flask for example, add 3mL of
cell solution into 17mL of cell media
8. Store cell culture flask in the incubator

In this project, cell passage numbers 7-17 were used in this study, following a
1:2, 1:3, 1:4, or 1:6 volume split to accommodate the timeline of the experiments. For
cell passaging between T25 (25#$" ) and T75 (75#$" ) flasks, the cell volume
calculations accounted for a 1:3 area ratio of the vials . The total volume of cells +
media in T75 cultures was 20mL and in the T25 was 7mL, based on recommendations
from the manufacturer (CytoOne).
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Collagen-coating of microporous membrane

The protocol was scaled from a 12-well transwell format (Bode et al., 2006) to
the 24-well transwell used throughout this project based on the area ratio of their
membranes: 1.12 #$" and 0.33 #$" , respectively (Corning). Each Transwell was
coated with a mixture of 7µL of human placental collagen (2.5 mg/mL) and 21µL of
70% Ethanol, on its microporous membrane. The collagen was obtained from Sigma
Aldrich (C5533-5MG), and stored at -20°C; thawing of the sample took place at room
temperature. All the process was carried out inside a class 2 biological safety hood
(SterilGARDIII Advance, The Baker Company).
After initial coating, the Transwell plates were placed in the running hood with
no lid for 2-3 hours until complete dryness. Next, the hood was closed and the plate
was left with no lid under the UV light for 1 hour. Finally, the plates were closed, sealed
with Parafilm M, wrapped in foil, and stored at 4°C up to use. Before use, the plates
were left in the running hood at room temperature for 30min.

Cell seeding on the Transwell membranes

BeWo cells were seeded in the Transwell inserts, either on the collagen-coated
matrix or directly over the microporous membrane, depending on the experiment and
the conditions tested. For more details on the experimental design, read the following
sessions.
Once seeded on the Transwells, cells were cultured in DMEM-F12 with no
phenol red (Gibco, ref 21041025) containing 10% FBS (Biowest). The presence of
phenol red in the culture media would increase the background fluorescence of samples
and interfere in fluorescent measurements. Thus, for the Transwell experiments, the
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same cell media, but with no phenol red, was used to culture the cell monolayer. The
media was prepared as previously described above.
The cell seeding process followed steps 1-6 of “cell culture and passaging”,
followed by the additional procedure:
1. Transfer cell solution into a 15mL conical and aliquot 100µL for cell
count
a. Cell count:
i.

Mix 10µL of cell solution + 10µL of trypan blue
(Corning, ref 25900CI) inside a well of a 96-well plate

ii.

Load 10µL into a chamber of a counting slide and insert
the slide into the cell counter (TC20 Automated Cell
Counter, BIO RAD)

2. Calculate volume of cell solution needed to make 1mL of cell stock
solution at 5,000,000 cells/mL:
*+& +- #%&& '+&./0+1 ($)) = 5 6 10#

#%&&'
1$)
6
$)
#%&& #+.1/

3. Aliquote the volume of cells calculated above into a vial and spin cells
down at 300g for 10min
a. In the meantime: warm up DMEM-F12 + 10%FBS no phenol
red (clear media), stored at 4°C, in a bead bath to 37°C
4. To prepare cell stock solution: remove supernatant (red media) and
resuspend cells in 1mL of warm, clear cell media, mixing vigorously
5. Add cell stock solution in the Tranwell based on the desired number of
seeded cells and complement with clear media up to the desired volume
a. Example: desired final volume of 100 uL
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Table 2: Example of cell solution stock and media volumes to be added during cell seeding

Desired number of seeded Volume of cell stock Volume of complementary
cells
solution (uL) per well
media (uL) per well
25,000

5

95

50,000

10

90

100,000

20

80

200,000

40

60

6. Add media to the bottom chamber
7. Store Transwell plate in the incubator

Optimization studies in the Transwell model

This optimization experiment aimed at finding a balance between utilizing the
least amount of seeding cells and incubating the cell layer for the least amount of time
to minimize the amount of material used and expedite the process of preparing the
Transwells for permeability studies.
Three variable conditions were tested in an iterative fashion: collagen coat vs.
no collagen coat on the Transwells; seeding cell density; incubation time. In previous
projects at the Ackerman Lab, researchers reported coating 24-well Transwell inserts
with human placental collagen and cell seeding of 20,000 cells (6 × 10$ cells/#$" ) and
100,000 cells (3 × 10! cells/#$" ) with respective incubation times of 7 days and 24
hours to reach monolayer confluency. This information, supported by methods reported
in the literature described in the introduction of this report, guided the selection of
reference values tested in the optimization experiments conducted for this project.
During all experiments, three polyester inserts without the Transwells were used
to track the cell growth using light microscopy for visual guidance about the monolayer
formation status. The inserts were prepared following the procedure of the experiment
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being conducted and quantities were scaled up based on the area ratio of the
insert:Transwell area.
Confluency of the Transwells was assessed through a permeability test using
FITC-dextran (40kDa): 750µL of clear cell media was added to the lower chamber and
100µL of 0.25mg/mL of FITC-dextran was added to the upper chamber. 40µL of
sample from the lower chamber was collected over time to track FITC-dextran transport
across the monolayer. Samples were stored at 4°C in a black 96-well plate with clear
bottom (Corning) and had their fluorescences measured in the plate reader (SpectraMax
Paradigm) using the Tune cartridge, fluorescent read mode, endpoint read type, and
known wavelengths for read: one wavelength pair, 485 nm for excitation and 535 nm
for emission. A half-dilution series of FITC-dextran at 2mg/mL was used as a standard
curve of the experiment.

1. Collagen vs. no-collagen coat
Two sets of Transwells were prepared, one with the collagen coat, and another
one without any coat, as depicted in Figure 8. For each set, four seeding cell numbers
were used in each well: 25,000 (7.57 × 10$ cells/#$" ); 50,000 (1.5 × 10! cells/#$" );
100,000 (3 × 10! cells/#$" ); 200,000 (6 × 10! cells/#$" ). The cell collagen coating
and seeding procedure were followed as described above. Confluency of the Transwells
was compared through the
FITC-dextran permeability
test, in which samples were
collected at times 0hr, 6hr,
and 24hr. The experiment Figure 8: Setup for testing collagen coating (a) vs. no coating (b)
on the Transwells

was conducted once, in
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duplicates, and there was no incubation time before the FITC-dextran was added to the
Transwells.

2. Cell seeding density
This variable aimed at evaluating the impact of the cell seeding density on the
rate at which the monolayer was formed, since the optimal set up would be to use the
minimal number of cells possible to form a cell layer in the least amount of time.
Based on the results of the coating experiment described above, the Transwells
were coated with human placental collagen, and seeded with BeWo cells, following the
protocols previously described. As depicted in Figure 9, four seeding cell numbers were
used in each well: 25,000 (7.57 × 10$ cells/#$" ); 50,000 (1.5 × 10! cells/#$" );
100,000 (3 × 10! cells/#$" ); 200,000 (6 × 10! cells/#$" ).
The collagen coating experiment above revealed FITC-dextran passage through
the monolayer after 24hrs of cell seeding. Thus, for this experiment, the Transwells
were incubated for 24 hrs prior to a permeability test, at 37°C, 5% CO2, and 95%
relative humidity. In the FITC-dextran permeability test, samples were collected at 0hr,
30min, 16hr, and 24hr. The experiment was conducted once, in duplicates.

Figure 9: Schematics representing the total number of cells added to each well: 25,000 (7.57 × 10!
cells/#$" ); 50,000 (1.5 × 10# cells/#$" ); 100,000 (3 × 10# cells/#$" ); 200,000 (6 × 10# cells/#$" ).

25

3. Incubation time
Lastly, this set of experiments aimed at finding the minimal number of days of
incubation time to reach monolayer confluency after cell seeding. Based on the
experiments designed for the other two variables described above, incubation time of
72 hrs (3 days) and 196 hrs (7days) were tested, building up on the previously data
collected for incubation times of 30min, 6hrs, 12 hrs, 24 hrs, 24hrs and 30min, 40hrs,
and 48hrs, through the collagen-coat and the cell seeding density experiments.
Transwells were coated with human placental collagen, and seeded with BeWo
cells, following the protocols previously described. Cell seeding of 200,000 cells/well
(6 × 10! cells/#$" ) was chosen based on the results of the “cell seeding density”
experiment. After cell seeding, the Transwells were incubated for 72 hrs or 196hrs prior
to a permeability test, at 37°C, 5% CO2, and 95% relative humidity. In the FITCdextran permeability test, samples were collected at 0hr, 30min, 12hr, and 24hr. The
experiment was conducted once, in duplicates. Transwells with collagen-coat but no
seeded cells were used as a positive control and Transwells with collagen-coat and
200,000 cells but no FITC-dextran were used as a negative control.

IgG translocation studies

The optimized Transwell model was used for IgG transport studies of the CMV
antibodies. A schematic of the experimental procedure is depicted in Figure 10.
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Figure 10: Overview of the IgG translocation study conducted in this project

First, the microporous membrane of the Transwell insert was coated with human
placental collagen, as described above. Then, 200,000 cells were seeded onto the
collagen coat and incubated for 72 hours in clear cell media, with an upper chamber
volume of 150µL and a lower chamber volume of 700µL, kept at 37°C, 5% CO2, and
95% relative humidity. At day 3, monolayer confluency was monitored by visual
inspection with light microscopy and confirmed through a permeability test using
FITC-dextran (40kDa): cell media was removed from the Transwells and replaced by
new clear cell media; 750µL was added to the lower chamber and 100µL of 0.25mg/mL
of FITC-dextran was added to the upper chamber. 40µL of sample from the lower
chamber was collected over time (0hr, 30min, 6hr, 12hr, 24hr) to track FITC-dextran
transport across the monolayer. At time 24hr, 40µL of the upper chamber was collected
to compare with the initial amount of FITC-dextran added to the Transwell system.
Transwells with collagen-coat but no seeded cells and FITC-dextran, and Transwells
with collagen-coat and 200,000 seeded cells after 3 days of incubation but no FITCdextran, were used as controls. The permeability test was conducted in duplicates.
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Samples were stored at 4°C in a black 96-well plate with clear bottom (Corning) and
had their fluorescences measured in the plate reader (SpectraMax Paradigm) using the
Tune cartridge, fluorescent read mode, endpoint read type, and known wavelengths for
read: one wavelength pair, 485 nm for excitation and 535 nm for emission. A halfdilution series of FITC-dextran at 2mg/mL was used as a standard curve of the
experiment.
Once the monolayer confluency was confirmed, the Transwells were used for
translocation studies of the CMV antibodies of interest, at day 4 of cell seeding. The
procedure followed similar steps of the permeability test described above: cell media
was removed from the Transwells and replaced by new clear cell media; 750µL was
added to the lower chamber and 150µL of 30µg/mL of each antibody was added to the
upper chamber. 40µL of sample from the lower chamber was collected over time (0hr,
30min, 6hr, 12hr, 24hr) to track the IgG transport across the monolayer. At time 24hr,
40µL of the upper chamber was collected to compare with the initial amount of
antibody added to the Transwell system. Samples were stored at 4°C until analysis.
Transwells with IgM (0.1 mg/mL, Southern Biotech) were used as negative
control of the experiment. This antibody translocation study was conducted in
duplicates and each Transwell contained only one type of antibody. Each control had
its own well and was not added to the wells containing the IgG antibodies, as the effect
of their interaction is still unknown and not the focus of this study. A layout of the setup
of plates and Tranwells used in this experiment is depicted on Figure 11.
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a)

b)

c)

Figure 11: Setup of Transwell plates for the IgG translocation study. (a) Detailed diagram of plate setup.
Each well contained only one antibody type, and the study was conducted in duplicates, using three 24well plates in total (b) Schematic of a Transwell with IgG antibody. (c) Schematic of a Transwell with
IgM antibody (negative control).

Luminex assay

Detection and quantification of IgG in the samples collected during the antibody
translocation studies took place through a Luminex immunoassay. First, magnetic
beads were pre-coated with analyte-specific capture antibodies. Then, the samples were
conjugated with the beads and PE-labeled detection antibodies and analyzed in the
Luminex instrument (Bio-Plex 3D suspension Array System, BIO RAD).
Four different beads were used in this assay, based on the specificity of the
mAbs selected for this project and the experimental controls. Antigens used were gB
(recombinant Human cytomegalovirus Glycoprotein B/gB Protein 1mg/mL, Sino
Biological Inc), gH pentamer (cytomegalovirus gH pentamer complex 1mg/mL, Native
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Antigen), anti IgG, and IgM. Beads for anti IgG and IgM were obtained from a
colleague in the lab. For gB and pentamer antigens, 400µL of beads were conjugated
for each, following these steps:
1. Vortex beads (10-15 seconds) and transfer the appropriate amount into
eppendorf tubes
a. Write down the bead number on top of the tube
2. Place the tube on the magnetic column until all beads stick to the magnet (30
sec- 1 minute). Remove buffer. Resuspend in 100 µL dH2O. Vortex beads (1030 sec) and place back on the magnet
3. Resuspend in 80 µL 100 mM NaPO4 pH 6.2 (activation buffer)
4. Add 10 µL EDC and NHS at 50 mg/mL (for both 10 mg into 200 µL activation
buffer)
a. Note: EDC is stored at -20C and NHS is stored at 4C. Keep sealed
(parafilmed and in the dessicator) when not in use. These reagents are
not very water soluble so make right before use and throw out if it’s left
out in solution for >30 min.
5. Wrap in foil and mix end-over-end for 20 minutes in rotation tray at room
temperature
6. Place the tube on the magnetic column. Wash 3X with 50 mM MES pH 5
(coupling buffer). (Wash by vortexing 30 seconds, put on magnetic column,
aspirate buffer)
7. Suspend in 100 µL coupling buffer
8. Add 25 ug protein per 400 µL beads and bring up to 500 µL coupling buffer
9. Wrap in foil and mix end over end for 2 hours in rotation tray at room
temperature
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10. Place on magnet, aspirate buffer. Wash 3X in PBS-TBN
11. Resuspend in 200 µL in PBS-TBN (PBS-TBN is purchased and stored at 4C),
wrap in foil, block 30 minutes with end-over-end mix in rotation tray at room
temperature
12. Wash once in PBS-TBN and resuspend in starting volume

Conjugated beads were stored at 4°C for two weeks up to use. Bead number 27
was conjugated with gB; bead number 28 was conjugated with Pentamer; bead 21 was
conjugated with anti IgG; bead number 44 was conjugated with IgM.
Prior to analysis, samples collected were
incubated with the conjugated beads and PElabeled secondary antibodies for detection to form
a bead-analyte-antibody complex as depicted in
Figure 12. Samples and standard curve samples for
IgG used mouse anti-human IgG Fc-PE (Southern
Biotech, cat 904009) as the secondary antibody. Figure 12: Overview of the Luminex
detection scheme. Figure adapted

Samples of IgM and IgM standard samples used from Thermo Fisher (LuminexTM

Bead-Based Immunoassays Drive
Immunoassays towards Highermouse anti-human IgM-PE (Southern Biotech, cat Content Biomarker Discovery, 2016).

902099).
Preparation of the sample and incubation with beads and secondary antibodies
followed the procedure used in the Ackerman Lab and detailed below. Operation of the
Luminex instrument was performed by Sweta Shrestha, a Ph.D candidate in the lab.
1. Add 5 uL of each sample into a 384-well plate
a. Only use clear bottom plates, magnet can’t pull down beads in white
bottom plates
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2. Prep bead master mix in assay wash buffer:
a. [# wells + 20] * # plates * 45 uL = uL assay buffer
b. [#wells + 20] * # plates * 500 beads/well ÷ 10,000 beads/ uL = uL of
each bead
3. Vortex and sonicate 1X bead mix for 30 seconds each. Add 45 uL bead mix to
each plate
4. Sticker cover the plate, wrap plate in foil, and incubate on shaker at 1000 rpm
for 2 hours
5. Prepare secondary antibody
a. Volume secondary:
i.

[#wells +15] * 40 uL/well = uL assay buffer

ii.

Note: antibodies should be used at 0.65 ug/mL. Only use PE
conjugated antibodies. Dilute antibody in the assay wash buffer,
cover with foil, and place in the fridge until being used

6. Prime plate washer into assay wash buffer. Wash plate (6 washes, takes 8
minutes)
7. Add 40 uL of secondary antibody per well. Vortex 30 seconds, sonicate 30
seconds. Repeat vortex/sonication
8. Cover plate with sticker cover, wrap in foil. Incubate 1 hr on shaker
9. Prime plate washer into sheath fluid and wash
10. Use plate washer to add 40 or 50 uL (or add manually)
a. If you added 40 uL sheath, pick up 35 uL. If you added 50 uL, pick up
42 uL
11. Bio-rad metal cover the plate and run on Luminex. No need to vortex or sonicate
12. Follow instructions for cleaning the Luminex prior to use
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Results
Optimization studies in the Transwell model

Determination of optimal parameters for creating a confluent cell layer in the
Transwells were guided by the data collected in the FITC-dextran permeability studies.
Fluorescence values were converted into estimated concentration (mg/mL) through
linear regression of a FITC-dextran standard curve. Analysis of the data revealed that
the final Transwell model must have a collagen coat, be seeded with 200,000cells/well
for a 24-well plate (6 × 10! cells/#$" ), and have an incubation of 3 days, at 37°C, 5%
CO2, and 95% relative humidity for cell growth into a confluent layer.

Collagen vs. no-collagen coat
FITC-dextran permeability across the Transwells revealed a significant
difference in the amount of analyte detected for collagen-coated inserts vs. inserts with
no coat, as can be seen by comparison of graphs in Figure 13 (a) and (b). After 24hrs
of cell seeding, for example, the Tranwells coated with 200,000 cells/well indicated a
final FITC-dextran concentration of 0.15mg/mL for no-coat Transwells and
0.027mg/mL for the collagen-coated Transwells. Therefore, the collagen-coated
Transwells were able to retain more FITC-dextran than no-coat Transwells, indicating
that a collagen matrix on the microporous membrane facilitates and/or expedites the
formation of a cell layer, and should be added to the steps of Tranwell preparation in
translocation studies. Raw data of this experiment in fluorescence units and a table with
the estimated concentrations plotted in Figure 13 can be found on Appendix I.
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a)

b)

c)

d)

Figure 13: Graphs of FITC-dextran permeability across the Transwells, assessed by concentration
plotted over time. This permeability test was performed right after cell seeding. (a) Graph of collagen
coated Transwells; (b) Graph of Transwelss with no coat; (c) Standard curve used to obtain values
plotted in graph (a); (d) Standard curve used to obtain values plotted in graph (b);

Cell seeding density
Comparison of FITC-dextran detection across Transwells seeded with different
cell densities revealed a huge gap in the permeability of the membranes. As can be seen
in graphs in Figure 14 (a) and (b), Transwells with less seeded cells allowed the passage
of more FITC-dextran across the monolayer, suggesting that FITC-dextran
permeability is inversely proportional to the number of seeded cells. For example, for
Tranwells seeded with 25,000 cells/well (7.57 × 10$ cells/#$" ), 0.099 mg/mL of FITCdextran was detected at 24hrs, while only 0.034 mg/mL of FITC-dextran was detected
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in the Transwells coated with 200,000 cells/well (6 × 10! cells/#$" ). As expected, this
data suggests that the more cells are added to the initial seeding of the Transwell
membranes, the faster the monolayer will reach confluency. Thus, seeding cell density
of 200,000 cells/well (6 × 10! cells/#$" ) was selected to expedite the monolayer
formation in the inserts. Raw data of this experiment in fluorescence units and a table
with the estimated concentrations plotted in Figure 14 can be found on Appendix II.

a)

b)

Figure 14: Graph of FITC-dextran permeability across Transwells with different seeding densities over
time. Transwells were incubated for 24hrs after cell seeding and prior to this permeability experimente.
(a) FITC-dextran concentration (mg/mL) over time. (b) Standard curve used to calculate the FITCdextran concentration.

35

Incubation time
Analysis of the data collected in the collagen-coat (Figure 13 (a)) and seeding
cell density (Figure 14 (a)) experiments revealed that monolayer confluency was not
obtained immediately after cell seeding or after a 24hrs incubation for any of the cell
seeding densities tested, since a significant amount of FITC-dextran was still being
detected in the samples collected. This indicated the need for more incubation time prior
to the permeability tests to allow for cell growth.
However, permeability data collected after 3 days of incubation (Figure 15 (a))
and after 7 days of incubation (Figure 15 (b)) for 200,000 cells/well revealed that
monolayer formation is reached after 3 days of cell seeding, since only 0.018 mg/mL
of FITC-dextran was detected in the samples. This was further confirmed by the data
collected in the IgG translocation studies, reported in the next section. Similar results
were obtained for the monolayers incubated for 7 days, with detection of 0.16mg/mL
of FITC-dextran, suggesting that even after 7 days of incubation, the monolayer is still
viable to be used in permeability studies.
Monolayer confluency should have indicated no FITC-dextran permeability.
However, the FITC-dextran molecule used was 40kDa, which is approximately three
times smaller than an IgG molecule (150kDa). The small size of the FITC-dextran used
in this experiment justifies some small, natural, permeability across the cell layer. Also,
since the Transwell plates were stored in the lab incubator, it might be possible that
other researchers disturbed the system by rearranging the plates inside the incubator.
Nevertheless, analysis of the raw fluorescence data (Appendix III) reveals that around
90% of the FITC-dextran originally added was being retained by the cell layer.
Therefore, small concentrations of FITC-dextran in the samples collected did not
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necessarily indicate the need of more incubation time to reach confluency. The
similarity in FITC-dextran concentration obtained for incubations of 3 days and 7 days
might suggest that the system possibly reached a plato of FITC-dextran permeability
across the cell layers, regardless of more incubation time. Raw data of this experiment
in fluorescence units and a table with the estimated concentrations plotted in Figure 15
can be found on Appendix III.

a)

c)

b)

d)

Figure 15: Graphs of FITC-dextran permeability across the Transwells, assessed by concentration
plotted over time. (a) Graph of Transwells after 3-day incubation; (b) Graph of Transwelss after 7-day
incubation; (c) Standard curve used to obtain values plotted in graph (a); (d) Standard curve used to
obtain values plotted in graph (b).
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Preferential IgG transferring in the BeWo Transwell model

Data of the FITC-dextran permeability test after 3 days of Transwell incubation
confirmed the confluency of the BeWo cell layer. As can be seen in Figure 16 (a), the
concentration of FITC-dextran detected in the samples replicate the concentrations
obtained in the prior permeability test after a 3-day incubation (Figure 15 (a)). Raw data
of this experiment in fluorescence units and a table with the estimated concentrations
plotted in Figure 16 can be found on Appendix IV.

a)

b)

Figure 16: Graph of FITC-dextran permeability across the Transwells after a 3-day incubation, assessed
by concentration plotted over time. (b) Standard curve used to obtain values plotted in graph (a).
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As can be seen in Figure 17, monolayer confluency of the Transwells after a 3say incubation was further confirmed by the absence of IgM antibodies detected in the
samples during the IgG translocation study, since the IgM control signal is aligned with
the IgM background signal. At the 24-hours point, average MFI of the two samples
collected indicated higher signal than the IgM background point, however, the standard
error bars at that point account for possible mistakes in sample manipulation or
collection, disturbance of the monolayer from previous sample collections, or
disturbance of the system by fellow researchers in the lab while in the incubator. Figure
17 further depicts the relative translocation efficiencies between the different IgG
antibodies studied, with IgG4 1G2 having the best transferring performance.

Figure 17: Antibody translocation across the BeWo Transwell layer. Mean fluorescence intensity (MFI)
plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the amount of antibody detected
in each sample. Anti-human IgG Fc-PE was used for the detection of IgG and anti-human IgM-PE was
used for the detection of IgM. The IgM control curve is plotted with its standard error bars.
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Further analysis of the data in Figure 17 by IgG subclasses (Figure 18) reveals
that IgG3 has the worst relative transferring, regardless of its specificity. On the other
hand, IgG4 and IgG2 showed the best relative transferring performance overall. For the
specificities 1G2 and 8I21, IgG4 indicated the highest preferential transferring. For
specificities ITC33 and 916, IgG2 transferring surpassed that of the other mAbs. Across
all specificities, IgG3 transferring fell behind IgG2 and IgG4, but surpassed that of
IgG3.

a)

b)

c)

d)

Figure 18: Antibody translocation across the BeWo Transwell layer by IgG subclass. Mean fluorescence
intensity (MFI) plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the amount of
antibody detected in each sample. (a) Plot of IgG1 mAbs. (b) Plot of Ig21 mAbs. (c) Plot of IgG3 mAbs.
(d) Plot of IgG4 mAbs.

Analysis of the data in Graph 5 by mAb specificities (Figure 19) reveals that
IgG 1G2 has the best transferring performance across the cell layer, regardless of its
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subclass. For the other specificities, no translocation pattern linking mAb specificity
and subclass was observed.
However, comparison of relative MFI values of each mAb specificity within the
same IgG subclass suggests preferential transferring of certain specificities depending
on the subclass analyzed. For IgG1, 8121 and 916 mAbs had the worst transferring
performance. For IgG2, 8I21 and ITC33 had the worst transferring performance. For
IgG3, 8I21 and 916 and had the worst performance. Finally, for IgG4, ITC33 and 916
had the worst translocation performance. Here, it is important to highlight that such
observations can be used as a guidance for future researchers but still require more data
to get quantified and statistically compared, since the experiment was run only once,
with duplicates.

a)

b)

c)

d)

Figure 19: Antibody translocation across the BeWo Transwell layer by mAb specificity. Mean
fluorescence intensity (MFI) plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the
amount of antibody detected in each sample. (a) Plot of 1G2 mAbs. (b) Plot of 8I21 mAbs. (c) Plot of
ITC33 mAbs. (d) Plot of 916 mAbs.
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Discussion
Studies about vertical immunization rely heavily on in-vitro models to
extrapolate physiological conditions of the human placenta for antibody translocation
studies. The BeWo Transwell model (Bode et al., 2006) presents itself as a reliable
model to represent perfusion preferences of substances that agree with other complex
ex-vivo models and to mimic the transplacental transport mechanism. However, despite
being a consolidated method, the BeWo Transwell preparation has a wide variation of
parameters. In this project, I optimized the BeWo Transwell model towards a more
time-efficient preparation to reach monolayer confluency by investigating three
variables: membrane coating, cell seeding density, and incubation time. The final ideal
parameters for the Transwell setup based on the variables studied are collagen-coat over
the microporous membrane, seeding cell density of 6 × 10! cells/#$" (200,000
cells/well for the 24-well plate), and incubation time of 72 hrs (3 days). Such results
agree with previous methods used by other researchers.
As previously investigated by Bill Law in the Ackerman lab and published by
Bode et al., adding collagen-coat to the Transwells is a necessary step towards preparing
the setup for confluency, which is expected from a biological standpoint since the
collagen works as a scaffold for the cells to grow.
The need of a higher cell seeding density to expedite the confluency of the
monolayer confirms our initial hypothesis that Transwells seeded with higher cell
densities will require less incubation time to reach monolayer confluency. The cell
seeding density value proposed, 6 × 10! cells/#$" (200,000 cells/well for the 24-well
plate), falls within previously reported cell seeding densities ranges discussed in the
introduction of this report (1.0× 10! cells/#$" to 1.0 × 10# cells/#$" ), which gives us
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confidence that such value will not underflow or overflow the surface area of the
Transwell and potentially affect the growth of a viable, healthy monolayer.
Finally, the incubation time proposed of 72 hrs (3 days) is in agreement with the
incubation time used by Aengenheister et al., which further supports our findings. This
incubation time is smaller than the 5-7 day incubation period that most research groups
previously reported (Bode et al., 2006; Cartwright et al., 2012; Huang et al., 2016;
Rytting et al., 2012), and meets our goal of optimizing the Transwell model in order to
achieve a confluent monolayer in the most time-efficient manner and expedite the
research process in biotech laboratories. Compatible FITC-dextran permeability results
from the 3-day incubation and the 7-day incubation suggests that even after 7 days of
incubation, the monolayer is still viable to be used in permeability studies. This means
that researchers can prepare their Transwells, incubate them for 3 days, run experiments
in a confluent cell layer, and, if needed, repeat experiments using the same cell layer up
to 7 days of cell seeding, which can further save up lab-work time.
IgG translocation studies using the BeWo Transwell model revealed that IgG3
had the worst relative transferring, regardless of its specificity, and that IgG4 and IgG2
demonstrate the best relative transferring performance overall. This contradicts our
initial hypothesis that IgG preferential transferring in the Transwell model would follow
the preferential transfer in-vivo: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et
al., 1994, 1996). One possible cause of such discrepancy might be a limitation in the
BeWo Transwell model in mimicking the IgG preferential transfer in-vivo. However,
given the physiological similarities of the cell line cultured on the Transwell inserts to
the placental tissue, it is likely that such results are being influenced by the IgG
specificity of the mAbs studied.
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In the past, studies about IgG-FcRn binding reported that the Fab domain does
not interfere with FcRn binding (Neuber et al., 2014). However, recent studies
characterizing the binding of 50 IgG molecules showed the opposite (Piche-Nicholas et
al., 2018). In 2018, Piche-Nicholas, Avery, King et al. demonstrated that domains distal
from the Fc can influence IgG binding to the FcRn domain and affect pharmacokinetics.
The researchers found out that the mutated IgG molecules in their variable domains had
their binding affinity to the FcRn altered in-vitro. Extending such findings into our
study, it can be hypothesized that IgG preferential transfering of the CMV mAbs
studied did not correlate with previously reported preferential transferring in-vivo due
to differences in antibody specificity. Up to this date, there is no study that attempted
to evaluate IgG preferential transferring in the context of CMV, limiting our ability to
compare our results with other published data within the same field of study.
However, the variable domain influence of IgG-FcRn binding is supported by
the data collected in this experiment, as each mAb specificity demonstrated a distinct
preferential translocation across the cell layer. The IgG 1G2, for example, had the best
transferring performance regardless of its subclass. It would be valuable to investigate
in the future how the combination of subclass and specificity affect the IgG-FcRn
binding, so we can leverage IgG translocation by designing mAbs with such
characteristics.

Recommendations for Future Work
Co-culture model in the Transwell inserts
Although the BeWo monolayer Transwell model is a consolidated method for
translocation studies in-vitro, it is not without its downsides. The single cell layer does
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not fully resemble the physiological structure of the placental barrier, which might limit
the ability of the model to offer predictions to in-vivo situations about larger and more
complex molecules such as antibodies. Co-culture models using different cell lines and
simulating the in-vivo dynamic environment have recently been developed to improve
the in-vivo resemblance of the Transwell model and have proven to be reliable systems
in translocation studies (Aengenheister et al., 2018; Huang et al., 2016; Levkovitz et
al., 2013). The model developed by et al., for example, uses a co-culture of BeWo cells
and microvascular human placental venous endothelial cell line (HPEC-A2) and allows
the translocation of a large variety of low to high molecular weight compounds and
nanoparticles (Aengenheister et al., 2018). In future studies, such a model should be
explored as a means of minimizing the physiological limitations of the single-layer
BeWo Transwell model used in this project. Other studies could potentially investigate
optimization parameters for the preparation of this co-culture model, following the
experimental approach used in this project and using the parameters of the single-cell
layer model as a starting reference, in order to assess the trade off between setting up a
more complex model with the cell seeding density needed and the Transwell incubation
time.

Preferential transferring of IgG across the Transwell monolayer
Despite observing relative differences in the transport of the antibodies studied,
further investigation must be conducted to quantify their permeability rates and
statistically assess whether such rates are significantly different.
While a different IgG subclass preferential transfering was observed in the
BeWo Transwell model than the one reported from in-vivo studies, with the current
data it is not possible to know whether such differences are a limitation of the BeWo
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Transwell model or a reflection of how the CMV-specific mAbs produced would
behave in-vivo. Thus, future studies should investigate how the IgG transferring in the
BeWo Transwell model compares to the IgG transferring in-vivo for the same antibody
subclasses and specificities. Since in-vivo studies of IgG transferring require complex
organization, one could select a previously published IgG transferring in-vivo and
replicate the transport study of the same antibody types in the Transwell model to
compare the resulting preferential transfering to those obtained in the published study.
Additionally, up to this date, transport studies using the BeWo Transwell model
reported mainly the investigation of nanoparticles and small molecules, and no study
was found comparing IgG transferring in the context of subclasses. Thus, further
investigation is required in order to assess whether the IgG preferential transfering
results obtained in this project would be replicated when studying the transport of mAbs
subclasses with other specificities.

CMV-specific studies
Over the last two years, there have been research efforts in the Ackerman Lab
in conjunction with collaborators around the world to study the 16 CMV mAbs
developed in-house and used in this project. There is still much work to further
characterize these antibodies and their immune response in the context of vertical
immunization. However, based on the results from the IgG translocation studies in this
project, future studies can focus on the further investigation of IgG2 and IgG4 with the
1G2 specificity, since these subclasses and specificity demonstrated preferential
transferring across the BeWo cell layer.
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In our study, it was not possible to establish a translocation pattern linking mAb
specificity and subclass. This might be because these two variables affect each other
during FcRn binding, resulting in a unique mAb specificity-subclass preferential
transferring for each of the antibodies studied. Given the differences in preferential
transferring observed, future studies could focus on investigating means of mutating
the complementarity-determining regions (CDRs) of the variable domains of the CMV
mAbs, just as the mutations reported by Piche-Nicholas, Avery, King et al. Altering
these IgG molecules can be used to leverage IgG-FcRn binding and subsequent
placental transport of mAbs of interest, based on other CMV-related studies.
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Appendices
Appendix I: Fluorescence data of collagen-coat vs. no coat experiment
Table 3: Raw fluorescence data of FITC-dextran permeability across the monolayer for the collagencoated transwells
Time
(hours)

25K cells 25K cells 50k cells 50k cells 100k cells 100k cells 200k cells 200K cells
(sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2)

0

2684362

2570768

2568483

2587135

2405238

2465883

2239656

2288823

6

2739840

2776988

2717706

2622114

2625878

2618534

2552624

2798200

24

2965496

2822920

2798498

2769424

2839154

2855156

2502318

2464379

24 (upper
chamber)

4865556

4454265

4623786

6795338

Table 4: Data of FITC-dextran standard curve for the collagen-coated Transwells

Concentration
(mg/mL)

Average
fluorescence

2

72627636

1

37619398

0.5

35328444

0.25

9889079.5

0.125

4925508

0.0625

2880597.5

0.03125

1584805

0.015625

856752.5

0

229803
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Table 5: Estimated concentration values plotted on Figure 13 (a)

Time
(hours)

25k cells

50k cells

100k cells

200k cells

0

0.03134925

0.03005469

0.02635364

0.0254794

6

0.0347537

0.03245099

0.03120982

0.02689414

24

0.03828682

0.03541839

0.03706258

0.02759699

Table 6: Raw fluorescence data of FITC-dextran permeability across the monolayer for no-coat
Transwells
Time
(hours)

25K cells 25K cells 50k cells 50k cells 100k cells 100k cells 200k cells 200K cells
(sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2)

0

2079660

2948110

3979249

3068706

233119

1978277

3762978

2874603

6

2852607

1073101

1938649

3247669

4913056

3361404

3846659

3972372

24

4241756

4263357

5908416

5235502

9146745

6197890

6365292

8938859

24 (upper
chamber)

7078102

2325686

10163590

13914240
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Table 7: Data of FITC-dextran standard curve for no-coat Transwells

Concentration
(mg/mL)

Average
fluorescence

2

75506062

1

67462414

0.5

21229726

0.25

10906391

0.125

4737093.5

0.0625

4040669.5

0.03125

2122909.5

0.015625

959025.5

0

282927.5

Table 8: Estimated concentration values plotted on Figure 13 (b)

Time
(hours)

25k cells

50k cells

100k cells

200k cells

0

0.08846851

0.05530423

0.09154334

0.07640661

6

0.09732082

0.10073324

0.07759457

0.06814913

24

0.15340494

0.15370828

0.12223336

0.10246146
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Appendix II: Fluorescence data of cell seeding density experiment
Table 9: Raw fluorescence data of FITC-dextran permeability across the monolayer in the cell seeding
density experiment
Time 25K cells 25K cells 50k cells 50k cells 100k cells 100k cells 200k cells 200K cells
(hours) (sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2) (sample 1) (sample 2)
0

136890

136000

132627

137189

137484

135979

134724

137733

0.5

166672

185497

196184

156327

186503

158093

175909

147022

6

556107

478493

545173

435046

410232

415413

449067

453542

16.5

696222

1294012

817441

682718

611175

657486

612103

606750

24

970639

2294710

878263

1394416

854021

1225160

836376

683498

1064883

982559

1838153

2411925

2310847

3010274

24 (upper
chamber)

1375710 1010764

Table 10: Data of FITC-dextran standard curve in the cell seeding density experiment

Concentration
(mg/mL)

Average
fluorescence

2

28813513

1

15042184.5

0.5

7608312

0.25

3619941.5

0.125

1899343

0.0625

1108383

0.03125

518120

0.015625

444446.5

0

168323
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Table 11: Estimated concentration values plotted on Figure 14(a)
Time
(hours)

25k cells

0

-0.003786195

-0.003892694 -0.003766343 -0.003801196

-0.001577364

0.5

-0.001039569

-0.00102772

-0.000317669 -0.002052521

-0.001577364

6

0.022603298

0.020719265

0.015364038

0.018030461

-0.001577364

16.5

0.055711301

0.03873262

0.030712357

0.028986755

-0.001577364

24

0.099887743

0.065496626

0.058792875

0.039415648

-0.001577364

50k cells

100k cells

200k cells

Cell Media
Background
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Appendix III: Fluorescence data of incubation time experiment
Table 12: Raw fluorescence data of FITC-dextran permeability across the monolayer for 3-day
incubation
Time
(hours)

No cells
No cells
200k cells 200k cells 200k cells no
(sample 1) (sample 2) (sample 1) (sample 2) FITC (sample 1)

200k cells no FITC
(sample 2)

0

146605

144798

143940

148099

146009

149782

0.5

180103

183185

154120

154843

146857

144531

6

548582

512235

240005

256386

160157

155630

12

727686

809442

380127

3893786

183837

155617

24

972128

1089004

584235

513602

216982

163768

3231987

3941344

233056

160918

24 (upper
chamber)

1268115 1230704

Table 13: Data of FITC-dextran standard curve for 3-day incubation

Concentration
(mg/mL)

Average
fluorescence

2

32024685

1

16471059.5

0.5

8272498

0.25

4238027.5

0.125

2211622.5

0.0625

1282174

0.03125

707061.5

0.015625

434305.5

0

223999
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Table 14: Estimated concentration values plotted on Figure 15(a)

Time
(hours)

No cells

200k cells

200k cells (no
FITC)

0

-0.0068487

-0.0068288

-0.0067112

0.5

-0.0045959

-0.0062984

-0.0068492

6

0.01726333

-0.0004247

-0.0060845

12

0.03219003

0.00813408

-0.0053429

24

0.04861135

0.01842346

-0.0040487

Table 15: Raw fluorescence data of FITC-dextran permeability across the monolayer for 7-day
incubation
Time
(hours)

No cells
No cells
200k cells 200k cells 200k cells no
(sample 1) (sample 2) (sample 1) (sample 2) FITC (sample 1)

200k cells no FITC
(sample 2)

0

132391

136400

134598

128115

138311

130421

0.5

178217

156328

145693

138310

131798

143953

6

373258

361768

181631

249714

135899

137067

12

550758

602925

248515

433816

132620

126710

24

883425

960068

341888

675139

184398

139677

4956796

3771570

162010

141129

24 (upper
chamber)

2233805 2283821
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Table 16: Data of FITC-dextran standard curve for 7-day incubation

Concentration
(mg/mL)

Average
fluorescence

2

33643225

1

16452020.5

0.5

8496595

0.25

4636241

0.125

2258745

0.0625

1213275.5

0.03125

736831.5

0.015625

403935.5

0

129373

Table 17: Estimated concentration values plotted on Figure 15(b)

Time
(hours)

No cells

200k cells

200k cells (no
FITC)

0

-0.0025943

-0.002655

-0.002596

0.5

-0.0006206

-0.0021917

-0.0023853

6

0.01140007

0.00218145

-0.0024689

12

0.02396631

0.0077557

-0.0028782

24

0.04467136

0.0158885

-0.0009349
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Appendix IV: Fluorescence data of FITC-dextran permeability prior to IgG
translocation investigations
Table 18: Raw fluorescence data of FITC-dextran permeability across the monolayer for the 3-day
incubation prior to IgG translocation studies
Time
(hours)

No cells
No cells
200k cells 200k cells 200k cells no
(sample 1) (sample 2) (sample 1) (sample 2) FITC (sample 1)

200k cells no FITC
(sample 2)

0

119694

136220

130039

131120

130674

132551

0.5

170328

187951

147501

146919

132019

147934

6

382816

437423

229592

260557

141857

142808

12

606506

540086

308448

379165

136834

139658

24

715954

858162

367687

587868

133408

136581

4116461

3182824

146155

133772

24 (upper
chamber)

1285219 1447977

Table 19: Data of FITC-dextran standard curve for the 3-day incubation prior to IgG translocation
studies

Concentration
(mg/mL)

Average
fluorescence

2

29004447

1

6216522.5

0.5

7109953

0.25

4843009.5

0.125

1849433

0.0625

1141383.5

0.03125

615212

0.015625

374903

0

131612.5
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Table 20: Estimated concentration values plotted on Figure 16

Time
(hours)

No cells

200k cells

200k cells (no
FITC)

0

-0.0042499

-0.0040746

-0.0040056

0.5

-0.0008283

0.0015

-0.0034464

6

0.01461305

0.00357954

-0.0032889

12

0.02552165

0.01017992

-0.0035621

24

0.03981196

0.01913609

-0.0037795
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